Glaucomatous visual field progression has both personal and societal costs and therefore
has a serious impact on quality of life. At the present time, intraocular pressure (IOP) is …

A recent hypothesis to enter the literature suggests that glaucoma is a neurodegenerative
disease. The basis for this has been the finding of central nervous system changes in …

Objective AR-13324 is a small-molecule inhibitor of Rho kinase and a norepinephrine
transporter. The objective of this 28-day study was to evaluate the ocular hypotensive …

Glaucoma is a progressive optic neuropathy and is the leading cause of irreversible
blindness worldwide. Over 60 million people were estimated to be affected with open-angle …

Purpose To investigate the intra‐ocular pressure (IOP)‐lowering effects and safety of 0.4%
ripasudil (K‐115), a Rho kinase inhibitor, twice daily for 52 weeks, in patients with open …

Glaucoma, a leading cause of blindness worldwide, is characterized by progressive optic
nerve damage, usually associated with intraocular pressure. Although the clinical …

Importance Ocular hypertension is an important risk factor for the development of primary
open-angle glaucoma (POAG). Data from long-term follow-up can be used to inform the …

Purpose To investigate the intra‐ocular pressure (IOP)‐lowering effects of a selective Rho
kinase inhibitor, ripasudil (K‐115), over 24 hr in patients with primary open‐angle glaucoma …

We are pleased to bring you the 5th edition of the Glaucoma Clinical Practice Guidelines.
Clinical practice guidelines are based on evidence (scientific grounds). It is a document that …

PURPOSE: To evaluate the ocular hypotensive efficacy of 0.05%, 0.1% and 0.25% AR-
12286 Ophthalmic Solutions in patients diagnosed with ocular hypertension or glaucoma …